Podcasts about Tice

Nate Tice joins Domonique and Charlie to break down the Bills' move to acquire DJ Moore for a second-round pick. They also dive into the NFL Draft conversation—discussing Kyler Murray's best landing spots, where Nate currently ranks Jeremiyah Love and Fernando Mendoza, and what the Chiefs need to do to make it back to the Super Bowl. Plus, more storytime with Charlie! 0:00 Intro6:52 What are your first impressions of the DJ Moore trade?13:26 What does this trade mean for Caleb and the Bears?24:07 Domonique shares his draft takes30:58 Do you see Jeremiyah Love as the best player on the board?35:54 Thoughts on the increased value of linebackers and safeties39:41 What does the McDuffie trade signal about the Rams and the Chiefs?55:08 If you were Kyler, how would you prioritize your options?1:00:04 What makes you so high on Fernando Mendoza?1:03:27 Storytime with Charlie Learn more about your ad choices. Visit podcastchoices.com/adchoices

Nate Tice joins Domonique and Charlie to break down the Bills' move to acquire DJ Moore for a second-round pick. They also dive into the NFL Draft conversation—discussing Kyler Murray's best landing spots, where Nate currently ranks Jeremiyah Love and Fernando Mendoza, and what the Chiefs need to do to make it back to the Super Bowl. Plus, more storytime with Charlie! 0:00 Intro6:52 What are your first impressions of the DJ Moore trade?13:26 What does this trade mean for Caleb and the Bears?24:07 Domonique shares his draft takes30:58 Do you see Jeremiyah Love as the best player on the board?35:54 Thoughts on the increased value of linebackers and safeties39:41 What does the McDuffie trade signal about the Rams and the Chiefs?55:08 If you were Kyler, how would you prioritize your options?1:00:04 What makes you so high on Fernando Mendoza?1:03:27 Storytime with Charlie Learn more about your ad choices. Visit podcastchoices.com/adchoices

Nate Tice joins Domonique and Charlie to break down the Bills' move to acquire DJ Moore for a second-round pick. They also dive into the NFL Draft conversation—discussing Kyler Murray's best landing spots, where Nate currently ranks Jeremiyah Love and Fernando Mendoza, and what the Chiefs need to do to make it back to the Super Bowl. Plus, more storytime with Charlie! 0:00 Intro6:52 What are your first impressions of the DJ Moore trade?13:26 What does this trade mean for Caleb and the Bears?24:07 Domonique shares his draft takes30:58 Do you see Jeremiyah Love as the best player on the board?35:54 Thoughts on the increased value of linebackers and safeties39:41 What does the McDuffie trade signal about the Rams and the Chiefs?55:08 If you were Kyler, how would you prioritize your options?1:00:04 What makes you so high on Fernando Mendoza?1:03:27 Storytime with Charlie Learn more about your ad choices. Visit podcastchoices.com/adchoices

Nate Tice joins Domonique and Charlie to break down the Bills' move to acquire DJ Moore for a second-round pick. They also dive into the NFL Draft conversation—discussing Kyler Murray's best landing spots, where Nate currently ranks Jeremiyah Love and Fernando Mendoza, and what the Chiefs need to do to make it back to the Super Bowl. Plus, more storytime with Charlie! 0:00 Intro6:52 What are your first impressions of the DJ Moore trade?13:26 What does this trade mean for Caleb and the Bears?24:07 Domonique shares his draft takes30:58 Do you see Jeremiyah Love as the best player on the board?35:54 Thoughts on the increased value of linebackers and safeties39:41 What does the McDuffie trade signal about the Rams and the Chiefs?55:08 If you were Kyler, how would you prioritize your options?1:00:04 What makes you so high on Fernando Mendoza?1:03:27 Storytime with Charlie Learn more about your ad choices. Visit podcastchoices.com/adchoices

Nate Tice joined Baskin and Phelps to break down his draft big board and explain why he thinks the Browns should keep their number 6 pick and use it on Georgia offensive tackle Monroe Freeling. He ranked the quarterbacks in this year's draft and discussed where he thinks various Ohio State players will wind up in the draft.

Hour 3 of Baskin and Phelps

Dr. Monty Pal and Dr. Andrea Apolo discuss practice-changing studies and other novel approaches in bladder, kidney, and prostate cancers that were presented at the 2026 ASCO Genitourinary Cancers Symposium. TRANSCRIPT Dr. Monty Pal: Hello and welcome to the ASCO Daily News Podcast. I'm your host, Dr. Monty Pal. I'm a medical oncologist, professor and vice chair of academic affairs at the City of Hope Comprehensive Cancer Center in Los Angeles.  And today is super exciting, we're highlighting key abstracts that were presented at the 2026 ASCO GU Cancers Symposium, and I'm just delighted to be joined by the chair of this year's meeting, who is also a dear friend, Dr. Andrea Apolo. Dr. Apolo serves within the Center for Cancer Research at the NCI as head of the Bladder Cancer Section, and she is also acting deputy chief of the Genitourinary Malignancies Branch.  Welcome, Andrea, it is so great to have you on the podcast. Dr. Andrea Apolo: Oh, thank you so much for having me. What a great ASCO that we had, it is really exciting, lots of really great data. So I look forward to chatting about it. Dr. Monty Pal: Excellent. And you know, our full disclosures are available in the transcript of this episode in case our listeners want to have a peek.  The theme of this year's GU meeting was "Patient-Centered Care: From Discovery to Delivery." I love that theme. And really, this is one of the most competitive meetings out there, more than 850 abstracts being presented on high-impact science. Andrea, I just wanted to get right into it and dive into what I think we both felt were some of the most exciting abstracts of the meeting.  And the first of those is one that I know is near and dear to your heart, being a bladder cancer expert yourself, and that is the KEYNOTE-B15 study presented by Matt Galsky. Can you give us a flavor for what that study entailed and some of the key results? Dr. Andrea Apolo: Yeah, I think this was kind of the missing study that we have been waiting for since we saw the EV-302 data in metastatic disease in the frontline setting. We wanted to know how well this combination would work in muscle-invasive bladder cancer patients. And we saw half of that puzzle, you can say half of the piece of the puzzle, when we saw the data at ESMO, the EV-303 data in patients that were cisplatin-ineligible. And then now we are getting the full story with patients that are platinum-eligible, cisplatin-eligible, with the EV-304 data. So that study randomized patients to receive chemotherapy, so different than the EV-303 where the patients were randomized just to receive the radical cystectomy. These patients were randomized to receive neoadjuvant EV plus pembro and then adjuvant EV plus pembro versus neoadjuvant gemcitabine and cisplatin with no adjuvant component to the control arm. So I think this is a really, really important study. Dr. Monty Pal: And share with us some of the results because this in my mind is definitely practice-changing. This is one of those studies that I think you walked into the office on Monday and you are like, "Okay, this is what I am doing now," right? Dr. Andrea Apolo: Yeah. So the study was positive. The primary endpoint was event-free survival, and it met the primary endpoint. The secondary endpoint of overall survival was also met. So really, really great results. Consistent with what we saw with EV-303, the median event-free survival was not reached for the EV plus pembro arm, and it was 48 months for the patients receiving gem-cis. And then looking at the 24-month estimated event-free survival, it was 79% for the EV plus pembro and 66% for the chemo, the gem-cis arm. And that was a hazard ratio of 0.5. So that is really exciting. That is the event-free survival. And then the overall survival, the medians were not reached for either arm, but when you look at the 24-month estimated overall survival, it was 87% for the EV plus pembro versus 81% for the gem-cis, and that was a hazard ratio of 0.65. So very positive study.  And then another question that we had was the pathologic CR rate. Very consistent with what we saw with the EV-303, the pathologic response rate was about 56% for the patients that received EV plus pembro and about 32%, 33% for the patients that received gem-cis. So very consistent with the findings that we have been kind of seeing in phase 2 studies, and this is a pT0N0, so that is important. Dr. Monty Pal: So Andrea, you know, I think that the big question in folks' minds is at this point, we see the data from NIAGARA, cis-gem-durva, we have now seen this data. Put it into context for us. Is there a patient in this day and age who maybe shouldn't get IO altogether, who should maybe get the NIAGARA regimen as opposed to EV-pembro in this context? What are your thoughts there? Dr. Andrea Apolo: Now, that is a great question. I would say with this data, it is very enticing to give EV pembro to our patients in the perioperative setting, and for that to be the new standard of care for all patients, regardless of cisplatin eligibility. So similar to what we saw with EV-302 really changing the standard of care in the frontline setting, I think these two studies, the EV-303 and the EV-304, change the standard of care for patients with muscle-invasive bladder cancer in the perioperative setting, and this should be the new standard of care if the patients don't have a restriction to receiving an immunotherapy. Dr. Monty Pal: I totally agree with that assessment. It is great to hear it from the expert's mouth as well. Thanks a lot for that, Andrea.  The next abstract I wanted to tackle is one that is, I would say, near and dear to my heart because I know these folks really well. It is led by the SWOG group, and this is SWOG S1602. The number there for the audience gives you a sense of how long the study has been running for. The 16 prefix means it is something that we kicked off back in 2016. So this study is really 10 years in the making, right? So Rob Svatek presented this data. It is interesting, right, because it addresses this issue of the BCG (Bacille Calmette-Guérin) shortage, right, where we have needed to sort of rely potentially on other alternative sources or regimens and so forth. Tell us about this trial, Andrea. Dr. Andrea Apolo: This is one of my favorite studies. We talked about putting it in the main oral abstracts, but we put it in one of the educational sessions that talked about non-muscle-invasive bladder cancer because we thought that would be the best audience for it. But it doesn't take away from how important this abstract is, and the tremendous effort that went into the study. Almost a thousand patients enrolled. I think 984 were eligible to enroll in this study. So it is a very high enrolling, randomized, cooperative group study in high-grade non-muscle-invasive bladder cancer. And really the study was designed to address two questions. One is the BCG shortage and can we use a different strain, Tokyo versus TICE? And whether there is a priming effect if you gave intradermal BCG to patients with non-muscle-invasive bladder cancer, can that enhance the effect if you gave it a little bit earlier? I think the study is really important, and it met its primary endpoint, which was it is not inferior to TICE. The findings were really terrific in terms of the outcomes. Numerically. When you look at the endpoint, it looked like the Tokyo strain was as good, if not maybe a little bit better, but not statistically significant than the TICE. And then they broke it down by carcinoma in situ, they broke it down by papillary tumors, and the Tokyo strain was non-inferior in both of those instances. But interestingly, the intradermal BCG did not change outcomes. There was really no priming effect, which was really backed up by pre-clinical data that there would be, but there wasn't a priming effect when the intradermal BCG was given in the Tokyo strain. So that was a really, really interesting finding. But a great study, really important outcomes in the field for non-muscle-invasive bladder cancer. Dr. Monty Pal: Totally. And it just seems like we can't get away from BCG, right? You know, as hard as we try, I mean, I appreciate the studies that sort of build on it that are emerging right now, but it seems like BCG at least for the foreseeable future is kind of here to stay, right? Dr. Andrea Apolo: It works. It is one of the most effective treatments we have for non-muscle-invasive bladder cancer. So, you know, I think it is here to stay and, you know, we need to find alternatives in terms of strains so we don't deal with this shortage that we have been dealing with for so many years now. Dr. Monty Pal: Yeah, indeed. Moving on to some of the other highlighted studies from the meeting, you had mentioned the EV-303 data, so we probably don't need to rehash that study design in much detail. But there was also a rapid oral abstract presented by Dr. Ullén that I think is of interest here, right, that really hones in on pathologic outcomes and DFS from that trial. Do you mind just outlining that for our listenership? Dr. Andrea Apolo: This is the KEYNOTE-905, also known as the EV-303 study. This is a follow-up to the EV-303 data looking at the pathologic response rates, looking at the downstaging effect, looking at the surgical margins after treatment with the neoadjuvant EV plus pembro in the 303. Now, remember in the 303, patients got three cycles of neoadjuvant EV plus pembro and then six cycles in the adjuvant setting. A little bit different than the 304, where they got four cycles, which is really kind of the standard in the neoadjuvant setting, and then five cycles in the adjuvant setting. So still a total of nine cycles. But in the 303, the treatment arm had no systemic therapy, so it was just radical cystectomy. And they looked at the negative margins that you get with the EV plus pembro treatment, which was 92.6% versus 79% with patients receiving just the surgery alone. And then the pathologic CR rate, there was more follow-up on that, it was 57% for the patients receiving EV plus pembro, and as we would expect, about 9% for the patients that just went on to surgery alone because you can achieve a pathologic response rate with TURBT alone. Then they looked at the pathologic downstaging, so anything less than a pT2, and that was 66% in the patients that received the EV plus pembro. So very interesting findings, and it is also really just nice to have now the EV-304 data, like I was saying, there were two pieces of it, the cisplatin-eligible and the cisplatin-ineligible, and just to have those contemporary controls are really important. How did the cisplatin-ineligible do versus the cisplatin-eligible patient in terms of the event-free survival and in terms of the overall survival? So I feel like now we have all of this data that we can kind of put together in the perioperative setting and we can really inform our patients a little bit more about their outcomes depending on whether they are cisplatin-eligible or not, which you know cisplatin-ineligible patients often just, they are sicker, they may have obstruction, their tumors may be larger, they just tend to be a more delicate population than the cisplatin-eligible patients. So not surprisingly, you know, we see that in the EV-303 the disease-free survival for the patients is pretty poor. So the disease-free survival that was reported for this follow-up of the specific abstract was 23.6 months for the patients that just got surgery, and it was not reached for the patients that had the EV plus pembro, and that was a hazard ratio of 0.37. Dr. Monty Pal: Excellent, excellent distillation. So Andrea, in the interest of time, I mean, we could probably talk about bladder cancer forever, but I am going to move us on to the subject of kidney cancer. We have two late-breaking abstracts, LITESPARK-011, which looked at lenvatinib and belzutifan versus cabozantinib in the advanced setting, and then we have an adjuvant study, LITESPARK-022, that looked at pembrolizumab with or without belzutifan in the adjuvant setting. Both studies positive. One for progression-free survival, the other for disease-free survival. Both I think making a big dent in how we treat kidney cancer. Can you tell us a little bit about that? Dr. Andrea Apolo: Yeah, we have been waiting for these trials for a long time. So one of the things that we have been talking about at GU ASCO is to have plenary sessions. And if we would have had a plenary session, these two abstracts would have been part of it because they are important data, really big studies where we are trying to improve the outcomes of our patients with kidney cancer. So the first one, the LITESPARK-011, like you said, this is for advanced renal cell carcinoma, clear cell renal cell carcinoma, where we really don't have a standard of care after IO therapy, right? So we give IO-IO, we give VEGF-IO, but we don't really have a good standard of care. We usually give monotherapy TKIs. So the combination of belzutifan and lenvatinib versus what a standard of care is, cabozantinib, is really an important question to ask. And you know, this is a pretty large study, about 750 patients were randomized. And belzutifan plus lenvatinib demonstrated an improvement in progression-free survival and overall survival versus cabozantinib, but not overall survival, at least not yet, is what the authors are saying. So for the progression-free survival, the hazard ratio was 0.7 and it was 14.8 months for the combination, belzutifan plus lenvatinib arm versus cabozantinib, which was 10.7 months. So I think that is significant. And for the overall survival, it did favor the combination again with a hazard ratio of 0.85. The median was 35 months versus 28 months for the monotherapy cabozantinib, but it did not reach statistical significance. And the authors said that this will be further tested at a final analysis, these were the interim results.  And for the overall survival, the overall survival was 53% for the combination versus 40%. This is significant. And the CR rates were lowish for both of them, it was like 5% for the combo and 1% for cabo monotherapy. So I think that the findings are important because we don't have a standard of care. And although there is no survival benefit, there was a trend. So I think this could be considered in patients that are fit, a treatment option for these patients in the later line settings. Dr. Monty Pal: Great points. I mean lots of great discussion around toxicity as well as efficacy. I mean certainly this is a regimen that may not be suitable for every patient in my portfolio, but certainly one to consider.  Now Andrea, let's shift focus to LITESPARK-022, the adjuvant trial that I mentioned previously. So this is again looking at pembrolizumab with or without belzutifan, met the primary endpoint of disease-free survival. What are your impressions there of the data? Dr. Andrea Apolo: Yeah, the data looks great. And this was a really large study, 1,800 patients were randomized, and the study met the primary endpoint of disease-free survival, benefiting the combination of pembro plus belzutifan. And that is really terrific. The medians were not reached for either arm. And in terms of the overall survival results, also the medians were not reached, but the hazard ratio was 0.78 and did not reach a statistical significance. So there was again a statistically significant improvement in disease-free survival for the combination of pembrolizumab plus belzutifan, but not an overall survival benefit.  So I guess, Monty, you know, we can kind of talk about what that means. There was a lot of discussion about belzutifan and some of the side effects, specifically anemia and managing anemia in this setting and requirements for transfusions. Generally, the authors said it was well tolerated, but we know that combination studies do have more toxicity. So it may be a select group of patients again, similar to the advanced setting, where we opt for a combination, possibly until we see more follow-up data in terms of the overall survival. Dr. Monty Pal: I have to agree with you. You know, in my group, we have been talking about a lot of pembrolizumab-based studies that are running right now, some through the NCI, some, you know, our own sort of homegrown investigator-sponsored trials, and you know, I think for the foreseeable future we are comfortable just maintaining pembrolizumab. Things might change if, for instance, we ultimately see a survival advantage emerge, but I just have my own personal doubts around that, that will be interesting.  Okay, so now we are going to move to the last disease category that we are going to cover, which is prostate cancer. So there, we have the long-awaited results from the PEACE-3 study. These are the final OS results from this trial looking at enzalutamide with or without radium-223 in metastatic castration-resistant prostate cancer. So Andrea, would love to get your perspectives on this. Dr. Andrea Apolo: Yeah, so this study had been presented before and we had seen positive results for the combination of enzalutamide and radium with some interim overall survival results also showing a benefit. But like you said, these are the final results with a median follow-up of 58 months. So it was really nice to see the final results. And with the combination of enzalutamide and six cycles of radium, it did show an improvement in overall survival with a hazard ratio of 0.76. The median overall survival increased from 32.6 months to 38.2 months with the combination. So that is really great. There was some crossing over of the overall survival curves around 18 months was still seen. And again, there was also an improvement in the rPFS with a hazard ratio of 0.71, and the median rPFS improved from 16.4 to 19 months with the combination. So, you know, we have been awaiting the final results, but we kind of knew a lot about the benefits of the combination. And it is something that is kind of slowly trickling into the community in terms of adapting it and using it. There is more buzz now about it and I think these overall survival results will hopefully shift the community into incorporating the combination in these patients. Dr. Monty Pal: Brilliant. So well said. I mean, Andrea, congratulations on a terrific meeting. You have really done it again. Incredible, incredible output from this year's ASCO GU. I just want to thank you for joining us on the program today. Dr. Andrea Apolo: Oh, thank you so much for having me, Monty. It was really a joy to work with the ASCO team and with all the investigators and the Education Committee and the Scientific Committee. Everyone was really outstanding. So to me it was an honor to be part of this meeting, and I am so happy that it was so successful and really presented some amazing data that I think will be practice-changing to our patients. Dr. Monty Pal: Oh, thanks a ton. And also a huge thanks to our listeners. If you enjoyed the content of today's podcast, please don't forget to like and subscribe to our channel wherever you listen to podcasts. Thanks so much. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:     Dr. Monty Pal   @montypal  Dr. Andrea Apolo @apolo_andrea  Follow ASCO on social media:          ASCO on X    ASCO on Bluesky         ASCO on Facebook          ASCO on LinkedIn          Disclosures:       Dr. Monty Pal:      Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview     Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical     Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis     Dr. Andrea Apolo: No disclosures to report.

Ee Milliounelach zu Steesel, Streidereie beim TICE an de Verdeelungskampf am Gesondheetssecteur, dat sinn eis Theemen an der Presserevue.

Ee Milliounelach zu Steesel, Streidereie beim TICE an de Verdeelungskampf am Gesondheetssecteur, dat sinn eis Theemen an der Presserevue.

Welcome to the Social-Engineer Podcast: The Doctor Is In Series – where we discuss understandings and developments in the field of psychology.  In today's episode, Chris and Dr. Abbie discuss decision fatigue—how making too many choices throughout the day drains mental energy and affects judgment. They explain how stress and lack of sleep make it worse, how it differs from burnout, and why leaders and parents are especially vulnerable. The episode also shares simple, practical strategies to reduce daily decisions, protect mental energy, and prioritize recovery.  [Mar 2, 2026]  00:00 - Intro  00:56 - Show Updates and Sponsors  02:35 - What Decision Fatigue Is  03:34 - Stress, Sleep, and Mental Energy  05:12 - Mental vs. Physical Limits  07:13 - Decision Fatigue vs. Burnout  10:22 - Leadership, Empathy, and Hard Decisions  14:33 - Prevention: Routines and Breaks  20:43 - Advisors and AI Caution  24:38 - Everyday Life and Parenting Load  27:23 - Recovery Outlets and Wrap-Up  28:49 - Closing and Next Month's Topic (Diet Culture)    Find us online:    LinkedIn: linkedin.com/in/dr-abbie-maroño-phd    Instagram: @DoctorAbbieofficial    LinkedIn: linkedin.com/in/christopherhadnagy    References:   Baumeister, R. F., Bratslavsky, E., Muraven, M., & Tice, D. M. (1998). Ego depletion: Is the active self a limited resource? Journal of Personality and Social Psychology, 74(5), 1252–1265. https://doi.org/10.1037/0022-3514.74.5.1252   Baumeister, R. F., & Tierney, J. (2011). Willpower: Rediscovering the greatest human strength. Penguin Press.   Danziger, S., Levav, J., & Avnaim-Pesso, L. (2011). Extraneous factors in judicial decisions. Proceedings of the National Academy of Sciences, 108(17), 6889–6892. https://doi.org/10.1073/pnas.1018033108   Davidson, R. J., & McEwen, B. S. (2012). Social influences on neuroplasticity: Stress and interventions to promote well-being. Nature Neuroscience, 15(5), 689–695. https://doi.org/10.1038/nn.3093   Fleming, S. M., & Dolan, R. J. (2012). The neural basis of metacognitive ability. Philosophical Transactions of the Royal Society B: Biological Sciences, 367(1594), 1338–1349. https://doi.org/10.1098/rstb.2011.0417   Hagger, M. S., Wood, C., Stiff, C., & Chatzisarantis, N. L. D. (2010). Ego depletion and the strength model of self-control: A meta-analysis. Psychological Bulletin, 136(4), 495–525. https://doi.org/10.1037/a0019486   Kahneman, D. (2011). Thinking, fast and slow. Farrar, Straus and Giroux.  

Bay Shore is a multi-campus, non-denominational church based in Millsboro, Delaware, with campuses in Rehoboth Beach and Fenwick Island — one church in multiple locations.Our mission is to connect to God, connect to people, and serve our community. We've created a culture where anyone can belong before they believe, offering a home of faith to those who don't have one.Rehoboth Campus:Address: 19331 Lighthouse Plaza, Rehoboth Beach, DE 19971Sunday Services: 8:30AM, 9:45AM, 11AM (each about an hour)Environments for babies (6 weeks–Pre-K) and kids (K–5th grade) are available during each service.• • Expect live music, practical messages, and a relaxed, casual atmosphere — come as you are!

In Ep. 2 of the Jets draft preview show, host Eric Allen is joined by Yahoo Sports draft guru Nate Tice for a wide-ranging conversation about the Green & White leading up to the 2026 NFL Draft. Tice takes a close look at the deep pool of receivers in the draft and how he ranks the top prospects at that position. He also discusses if Notre Dame running back Jeremiyah Love is a viable option for the Jets and he compares one of the quarterbacks in this year's draft to Jets Legend Chad Pennington.See omnystudio.com/listener for privacy information.

Bay Shore is a multi-campus, non-denominational church based in Millsboro, Delaware, with campuses in Rehoboth Beach and Fenwick Island — one church in multiple locations.Our mission is to connect to God, connect to people, and serve our community. We've created a culture where anyone can belong before they believe, offering a home of faith to those who don't have one.Rehoboth Campus:Address: 19331 Lighthouse Plaza, Rehoboth Beach, DE 19971Sunday Services: 8:30AM, 9:45AM, 11AM (each about an hour)Environments for babies (6 weeks–Pre-K) and kids (K–5th grade) are available during each service.• • Expect live music, practical messages, and a relaxed, casual atmosphere — come as you are!

Letošní rok je pro Přeštice na jižním Plzeňsku výjimečný – město si připomíná 800 let od první písemné zmínky. Připravený je bohatý program, který je rozložený do průběhu celého roku. V těchto dnech je navíc přímo v Přešticích mimořádně vystavený originál královské listiny z roku 1226.

Letošní rok je pro Přeštice na jižním Plzeňsku výjimečný – město si připomíná 800 let od první písemné zmínky. Připravený je bohatý program, který je rozložený do průběhu celého roku. V těchto dnech je navíc přímo v Přešticích mimořádně vystavený originál královské listiny z roku 1226.Všechny díly podcastu Náš host můžete pohodlně poslouchat v mobilní aplikaci mujRozhlas pro Android a iOS nebo na webu mujRozhlas.cz.

Letošní rok je pro Přeštice na jižním Plzeňsku výjimečný – město si připomíná 800 let od první písemné zmínky. Připravený je bohatý program, který je rozložený do průběhu celého roku. V těchto dnech je navíc přímo v Přešticích mimořádně vystavený originál královské listiny z roku 1226.

Andrew Siciliano deep dives on the 2026 NFL Draft with Nate Tice & ESPN's Matt Miller. Andrew kicks things off with Nate Tice as they parse through Nate & Charles McDonald's latest mock draft and cover a few of the more interesting selections, including EDGE Rueben Bain Jr. going second overall to the New York Jets, RB Jeremiyah Love in the top ten, EDGE David Bailey to the Washington Commanders and more. Next, Andrew & Nate set their sites on Indianapolis for the NFL Combine as Nate gives his top prospects he's most excited to watch test next week.Later, Andrew is joined by ESPN's Matt Miller to get his thoughts on the draft (including Ty Simpson, Caleb Downs and more) before talking through his latest NFL mock draft.(6:55) - Nate Tice breaks down latest NFL mock draft(21:55) - Nate's top prospects to watch at the NFL Combine(44:00) - Matt Miller talks latest NFL mock draft Subscribe to Inside Coverage on your favorite podcast app:

There were so many coaching changes this past month we decided to split our annual coaches show in two parts. Nate Tice joins Matt Harmon to breakdown every single head coach and offensive coordinator change in the NFC. Harmon and Tice identify which changes they like, they're fine with and the one's they are most skeptical of for fantasy purposes in 2026. (3:00) - NFC coaching changes this offseason: I like it, It's fine and I'm skeptical  (6:18) -  I like it - Cardinals HC Mike LaFleur  (20:45) - I like it - Commanders OC David Blough  (30:00) - I like - Falcons HC Kevin Stefanski + OC Tommy Rees (38:30) - It's fine - Lions OC Drew Petzing  (47:30) - It's fine - Buccaneers OC Zac Robinson  (56:00) - It's fine - Seahawks OC Brian Fleury  (1:02:00) - I'm skeptical - Eagles OC Sean Mannion  (1:11:30) - I'm skeptical - Giants HC John Harbaugh + OC Matt Nagy      Subscribe to the Yahoo Fantasy Forecast on your favorite podcast app:

There were so many coaching changes this past month we decided to split our annual coaches show in two parts. Nate Tice joins Matt Harmon to breakdown every single head coach and offensive coordinator change in the AFC. Harmon and Tice identify which changes they like, they're fine with and the one's they are most skeptical of for fantasy purposes in 2026.(1:30) - AFC coaching hires we like: Ravens HC Jesse Minter + OC Declean Doyle, Bills HC Joe Brady (27:30) - AFC coaching hires we like: Raiders HC Klink Kubiak, Chargers OC Mike McDaniel(47:05) - AFC coaching hires that are fine: Browns HC Todd Monken, Dolphins OC Bobby Slowik, Titans OC Brian Daboll(1:13:15) - AFC coaching hires that we are skeptical of: Chiefs OC Eric Bieniemy, Steelers HC Mike McCarthy, Jets OC Frank Reich Subscribe to the Yahoo Fantasy Forecast on your favorite podcast app:

Bay Shore is a multi-campus, non-denominational church based in Millsboro, Delaware, with campuses in Rehoboth Beach and Fenwick Island — one church in multiple locations.Our mission is to connect to God, connect to people, and serve our community. We've created a culture where anyone can belong before they believe, offering a home of faith to those who don't have one.Rehoboth Campus:Address: 19331 Lighthouse Plaza, Rehoboth Beach, DE 19971Sunday Services: 8:30AM, 9:45AM, 11AM (each about an hour)Environments for babies (6 weeks–Pre-K) and kids (K–5th grade) are available during each service.• • Expect live music, practical messages, and a relaxed, casual atmosphere — come as you are!

With talk of an early UK election swirling, Reform Deputy Leader Richard Tice joins Merryn Somerset Webb to make the case that his party is ready to govern. Tice argues that Reform UK, which is leading in the polls, is gearing up policy “working groups” and road-testing power in local councils. He claims day-one moves like serving notice to leave the European Commission on Human Rights, scrapping the Human Rights Act and abandoning a net-zero approach to global warming would help cut energy bills—while he hints at a broader reset for UK markets, pensions, regulation and crypto.See omnystudio.com/listener for privacy information.

Hour 3 1:12 - Jayden Daniels Hints at ASU Reunion: Aiyuk to Washington? 14:18 - Calls on Brandon Aiyuk to DC 33:07 - Where Does Sam Darnold Rank in the NFC?

Bay Shore is a multi-campus, non-denominational church based in Millsboro, Delaware, with campuses in Rehoboth Beach and Fenwick Island — one church in multiple locations.Our mission is to connect to God, connect to people, and serve our community. We've created a culture where anyone can belong before they believe, offering a home of faith to those who don't have one.Rehoboth Campus:Address: 19331 Lighthouse Plaza, Rehoboth Beach, DE 19971Sunday Services: 8:30AM, 9:45AM, 11AM (each about an hour)Environments for babies (6 weeks–Pre-K) and kids (K–5th grade) are available during each service.Expect live music, practical messages, and a relaxed, casual atmosphere — come as you are!

February 5th, 2026 Follow us on Facebook, Instagram and X Listen to past episodes on The Ticket’s Website And follow The Ticket Top 10 on Apple, Spotify or Amazon MusicSee omnystudio.com/listener for privacy information.

Sheil is joined by The Ringer's Billy Gil and Nate Tice from Yahoo Sports' Football 301 show to talk about, analyze, and debate the players and moments they're predicting will prove pivotal in the outcome of Super Bowl LX.(2:12) Bold predictions for Super Bowl LX(2:52) Drew Lock(5:46) Drake Maye(11:52) Klint Kubiak(19:47) The Patriots(24:23) Mike Vrabel(25:49) Doug Baldwin(27:20) Jaxon Smith-NjigbaThe Ringer is committed to responsible gaming. Please visit www.rg-help.com to learn more about the resources and helplines available.Host: Sheil KapadiaGuests: Billy Gil and Nate TiceProducer: Chris SuttonVideo: Cory McConnell and Stefano SanchezProduction Supervision: Conor Nevins and Arjuna Ramgopowell Learn more about your ad choices. Visit podcastchoices.com/adchoices

Nick Kostos is joined by Scott Hanson, Nate Tice, Greg Hill & Jermaine Wiggins!

Yahoo's Nate Tice joins the show to discuss his life growing up in football as a son of an NFL Head Coach. Plus, Nate tells us how he got started in media, and previews Seahawks vs. Patriots.

(00:00) Zolak & Bertrand start the hour - LIVE from Radio Row - by rehashing some audio from Adam Schein from earlier in the season in which he stated the Patriots were frauds. Has your mind changed on the Patriots based on their playoff run and easy schedule?(3:46) Adam Schein, CBS Sports broadcaster, joins Zolak & Bertrand to defend his take on the Patriots and discusses the Patriots path to get here. (20:39) Nate Tice, from Yahoo Sports, joins the show to preview Super Bowl LX this Sunday. (31:12) The guys recap the slew of guests thus far on an eventful day on Radio Row. Beetle asks, “Are you worried about this Super Bowl being a boring game?”See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Reggie Adetula & John Lopez are joined by Nate Tice & react to his takes! Later, Reggie & John are also joined by Adam Shein as he gives his takes on the Texans & CJ Stroud!

Reggie Adetula & John Lopez are joined by Nate Tice!

What is the ceiling of Baker Mayfield? Nate Tice of Yahoo Sports drops by!

We go through the wide receiver defensive back matchup between the Seahawks and Patriots. The Seahawks have JSN and the Patriots defender is Christian Gonzalez, who will have the biggest impact? // The Timeline: Jerry Dipoto has eluded to the team looking to make one more move before spring training starts, Tennessee basketball head coach Rick Barnes wonders if some of his players are betting on games. // Yahoo Sports Nate Tice joins the show to give us his take on the Super Bowl being a matchup between the Seahawks and Patriots, Klint Kubiak possibly going to the Raiders, and the comparison of Mike Macdonald to Mike Vrabel. // Four Down Territory: 1st Down: Who will need to have a big game Sunday? 2nd Down: How should the defense attack Drake? 3rd Down: What stat is misleading? 4th Down: Anything stand out from Nate Tice?

Nate Tice from NFL Network joins G&D to take a look at the Commanders from a national perspective.

2.2.26 Hour 2 1:00- Nate Tice from NFL Network joins G&D to take a look at the Commanders from a national perspective. 20:00- The Vikings fired GM Kwesi Adofo-Mensah over the weekend, and one of the reasons floated out was pretty wild. 37:00- What's going on in our lives that has nothing to do with sports?

Former University of Wisconsin QB now NFL Writer for Yahoo, Nate Tice joins the Nation live from Super Bowl Radio Row full 958 Mon, 02 Feb 2026 23:20:58 +0000 XFmlxZDYW7Ykq347Vt3IMDYW9MeZknCP nfl,dallas cowboys,sports GBag Nation nfl,dallas cowboys,sports Former University of Wisconsin QB now NFL Writer for Yahoo, Nate Tice joins the Nation live from Super Bowl Radio Row The G-Bag Nation - Weekdays 10am-3pm 2024 © 2021 Audacy, Inc. Sports False

1st hour of the G-Bag Nation: Latest Headlines; GBAG of the DAY Champ Replay; Woolly Bully's Top 10; Former College QB now NFL writer for Yahoo, Nate Tice joins the Nation full 2828 Mon, 02 Feb 2026 23:10:20 +0000 WowAwfnQcrQU4nmZk57O6o3MAzm5F05C sports GBag Nation sports 1st hour of the G-Bag Nation: Latest Headlines; GBAG of the DAY Champ Replay; Woolly Bully's Top 10; Former College QB now NFL writer for Yahoo, Nate Tice joins the Nation The G-Bag Nation - Weekdays 10am-3pm 2024 © 2021 Audacy, Inc.

Send us a textWhat if the next 30 days weren't about fixing everything… but about proving something to yourself? In this episode, I invite you into a challenge that's intentionally simple, quietly powerful, and very different from the usual “do more, be more” approach. If you've ever felt overwhelmed by goals, burned out by resets, or frustrated that motivation fades faster than you expected—this conversation is for you.If you're ready for a challenge that travels with you, adapts to real life, and strengthens your relationship with yourself—press play and walk with me.Quote of the Week:“Challenges are what make life interesting and overcoming them is what makes life meaningful.” — Joshua J. MarineCitations:Bandura, A. (1997). Self-efficacy: The exercise of control. W.H. Freeman.Baumeister, R. F., Bratslavsky, E., Muraven, M., & Tice, D. M. (1998). Ego depletion: Is the active self a limited resource? Journal of Personality and Social Psychology, 74(5), 1252–1265.Let's go, let's get it done. Get more information at: http://projectweightloss.org

Dave and Alex welcome Corey Annan and Bakari Tice onto the show and we talk about their athletics journeys, NJ XC and Track and more!

This episode join us as we pick our top films of the year with guest, award winning screenwriter Tyler Tice.  He penned a Netflix vampire movie ‘The Day Shift'.  

Week 16 is upon us and it's time for another edition of 'The Fantasy Film Room' with Matt Harmon and Nate Tice. The dynamic duo identify matchups that have them stressed in Week 16. Tice also provides 'fantasy watch guide' for the top prospects in this year's CFP. The two then preview a massive divisional TNF matchup between the Los Angeles Rams and Seattle Seahawks. Joel Smyth then joins the show to share his 5 players that you need to keep an eye on in fantasy this weekend.(3:30) - Fantasy Fallout: Tua benched in Miami, Quinn Ewers takes over as QB1(17:30) - Fantasy Film Room: Matchups we are STRESSED about in Week 16 (18:30) - Lions WRs vs. Steelers DBs (29:10) - Chargers WRs vs. Cowboys defense (35:40) - Terry McLaurin vs Quinyon Mitchell (39:25) - Cowboys WRs vs. Chargers DBs(46:25) - Jaguars WRs vs. Broncos DBs(51:20) - CFP fantasy prospects to know(1:07:40) - TNF preview: Rams @ Seahawks(1:18:15) - Buzz is Building: 5 players to watch in Week 16   Subscribe to the Yahoo Fantasy Forecast on your favorite podcast app:

Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-462 Overview: In this episode, we examine migraine—a leading cause of disability worldwide that is often underdiagnosed and undertreated in primary care. You'll learn how to distinguish migraine from other headache disorders, identify who is most affected, and explore both acute pharmacologic options and preventive strategies that can reduce attack frequency and improve patients' quality of life. Episode resource links: El Hussein, M. T., & Fraser, L. (2025). Pharmacologic Management of Migraine in Primary Care: Nurse Practitioner Guide. The Journal for Nurse Practitioners, 21(9), 105501. Qaseem, A., Tice, J. A., Etxeandia-Ikobaltzeta, I., Wilt, T. J., Harrod, C. S., Cooney, T. G., ... & Yost, J. (2025). Pharmacologic treatments of acute episodic migraine headache in outpatient settings: a clinical guideline from the American College of Physicians. Annals of internal medicine, 178(4), 571-578. Charles, A. C., Tepper, S. J., & Ailani, J. (2025). State of the art in the management of migraine—A response to the American College of Physicians migraine preventive treatment guideline. Headache: The Journal of Head and Face Pain. Vélez-Jiménez MK, et al. Comprehensive Preventive Treatments for Episodic Migraine: Systematic Review. Front Neurol. 2025 Lanteri-Minet, M., Casarotto, C., Bretin, O., Collin, C., Gugenheim, M., Raclot, V., ... & Lefebvre, H. (2025). Prevalence, characteristics and management of migraine patients with triptan failure in primary care: the EMR France-Mig study. The Journal of Headache and Pain, 26(1), 153. Guest: Mariyan L. Montaque, DNP, FNP-BC   Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com  

Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-462 Overview: In this episode, we examine migraine—a leading cause of disability worldwide that is often underdiagnosed and undertreated in primary care. You'll learn how to distinguish migraine from other headache disorders, identify who is most affected, and explore both acute pharmacologic options and preventive strategies that can reduce attack frequency and improve patients' quality of life. Episode resource links: El Hussein, M. T., & Fraser, L. (2025). Pharmacologic Management of Migraine in Primary Care: Nurse Practitioner Guide. The Journal for Nurse Practitioners, 21(9), 105501. Qaseem, A., Tice, J. A., Etxeandia-Ikobaltzeta, I., Wilt, T. J., Harrod, C. S., Cooney, T. G., ... & Yost, J. (2025). Pharmacologic treatments of acute episodic migraine headache in outpatient settings: a clinical guideline from the American College of Physicians. Annals of internal medicine, 178(4), 571-578. Charles, A. C., Tepper, S. J., & Ailani, J. (2025). State of the art in the management of migraine—A response to the American College of Physicians migraine preventive treatment guideline. Headache: The Journal of Head and Face Pain. Vélez-Jiménez MK, et al. Comprehensive Preventive Treatments for Episodic Migraine: Systematic Review. Front Neurol. 2025 Lanteri-Minet, M., Casarotto, C., Bretin, O., Collin, C., Gugenheim, M., Raclot, V., ... & Lefebvre, H. (2025). Prevalence, characteristics and management of migraine patients with triptan failure in primary care: the EMR France-Mig study. The Journal of Headache and Pain, 26(1), 153. Guest: Mariyan L. Montaque, DNP, FNP-BC   Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com  

This week on the PicklePod, Zane and Tice dive into one of the wildest slates of global pickleball we've had in a while — even if half of it was nearly impossible to find online. We break down tournaments in Vietnam, Australia, and China, plus look ahead to the biggest December events in the pickleball world. From the mystery surrounding DJOY Vietnam, to Bondi's underdog run at MLP Australia, to new partnerships forming for Hangzhou, we're covering everything the pickleball diehards want to know. And yes… we attempt the impossible: building the worst pickleball player in the top 20. We also talk Dink Awards, Minor League Nationals, Juniors vs. the Breakers, the Pickleball Marathon world record attempt, APP Tour Championships, Daytona chaos, and the freshest international storylines in the sport. Topics include: • D-JOY Vietnam recap • MLP Australia finals + Bondi's run • APP's new Global Pickleball Alliance + rankings • December pickleball schedule: Minor League Nationals, Dink Awards, Hangzhou Open, APP Championships, PPA Daytona • Junior phenoms changing the game • Building the worst top-20 pro (fan-suggested segment!)

Stacy and Curtis are joined by Yahoo Sports’ Nate Tice to get his thoughts on what makes this year’s Seahawks a great team and why he is still optimistic about Sam Danrold, they give you their thoughts on the Patriots tenth straight win and Eagles OC Kevin Patullo’s house getting egged in Headlines Rewrites, they bring you the biggest stories around the NFL, including the recently unretired Frank Ragnow’s season ending injury, and they break down how many wins the Seahawks would need to win the NFC West. 

This week on the PicklePod, Zane and Tice break down one of the wildest weekends of pickleball we've seen all year. The Lakeland Open delivered everything—controversial calls, insane comebacks, breakout stars, near meltdowns, and another dominant run from the tour's heavy hitters. We kick things off with Part 2 of last week's viral Create-a-Player Draft, where Zane and Tice build the ultimate women's pickleball player. 11 categories. No duplicate picks. Maximum trash talk. The community demanded a rematch…and Tice wants revenge. From there, the guys get into all the biggest stories: Lakeland Open Chaos – The now-infamous Roscoe/Hunter match point controversy – Luca Mack's eye-opening semifinal run – Noe's first PPA medal – The 17-point swing that shocked the men's doubles bracket Nationals Recap – Jill Braverman's viral line call – Why a $225K event ran with no replays – PK's first singles title • Global Pickleball Politics – The WPF, GPF, UWPF alphabet soup explained – What a potential merger means for the Olympics – Why governing bodies matter more than people realize Lakers Pickleball Tournament – Yes… the Lakers ran their own pickleball event – Luka Dončić credits pickleball for slimming down – Why NBA players might be the worst body type for dinking • Debate of the Week: If Ben and Anna Leigh were forced to split up in 2026… who wins more mixed titles? Zane and Tice go deep on the chessboard of future partnerships.

Nate Tice of Yahoo Sports joins Bomani Jones. First, they discuss Shedeur Sanders' making his debut start against the Las Vegas Raiders and why they believe he needs to get out of Cleveland to have any shot at NFL success. Later, they break down the Chiefs taking on the Indianapolis Colts and who they think has the edge in that AFC matchup. Finally, they talk about Matt Lafleur potentially coaching for his job, the Cowboys' shocking success with George Pickens, and whether or not there is a great NFL prospect in the 2026 NFL draft. 00:50 - Shedeur Starts for Browns 23:30 - Chiefs on the brink 33:00 - What's going on in Green Bay? 40:20 - Can the Cowboys upset the Eagles Learn more about your ad choices. Visit megaphone.fm/adchoices

This week, The Naked Week shoehorns an agenda, gets out of jail free, and in a genuine Radio 4 first - Taylor Swift pays a visit to the studio!From host Andrew Hunter Murray and The Skewer's Jon Holmes, Radio 4's newest Friday night comedy The Naked Week returns with a blend of the silly and serious. From satirical stunts to studio set pieces via guest correspondents and investigative journalism, it's a bold, audacious take not only on the week's news, but also the way it's packaged and presented.Host: Andrew Hunter Murray Guests: Paul Dunphy, Taylor Swift (no, really!)Investigations Team: Cat Neilan, Cormac Kehoe, Freya ShawWritten by: Jon Holmes Katie Sayer Gareth Ceredig Jason Hazeley James KettleAdditional Material: Karl Minns Ali Panting Helen Brooks Molly Punshon Kevin Smith David RiffkinLive Sound: Jerry Peal Post Production: Tony Churnside Clip Assistant: David Riffkin Production Assistant: Molly PunshonAssistant Producer: Katie Sayer Producer and Director: Jon HolmesExecutive Producer: Phil Abrams.An unusual production for BBC Radio 4

It's a special edition of the Fantasy Film Room with Matt Harmon and Nate Tice as the two play the 'Blame Game' with six of the most important offenses in fantasy that have fallen on hard times. Harmon and Tice assign blame between the play caller, QB, supporting cast and randomness for why things aren't working for these six offenses. Joel Smyth joins the show later to provide five names you need to keep an eye on in Week 11. Subscribe to the Yahoo Fantasy Forecast on your favorite podcast app:

It's a special edition of the Fantasy Film Room with Matt Harmon and Nate Tice as the two do their midseason review. Harmon and Tice share their four biggest lessons and surprises from the first half of the season and then share their four biggest predictions for the second half. Joel Smyth joins the show later to identify 5 players you need to keep an eye on in fantasy in Week 10.(2:00) - Matt and Nate's biggest lessons and surprises from first half of the season(34:30) - Matt and Nate's predictions for second half of the season(59:30) - TNF preview: Raiders @ Broncos(1:07:50) - Buzz is Building: 5 players to watch in Week 10 Subscribe to the Yahoo Fantasy Forecast on your favorite podcast app:

Nate Tice of Yahoo Sports and the Football 301 podcast joins Beau Allen to yap some football midweek! Nate and Beau discuss the success of the Kansas City Chiefs coming off their Monday Night Football victory over the Washington Commanders, and the dominating connection of Rashee Rice and Patrick Mahomes. Then the fellas dive into Drake Maye's play - his deep ball passing is literally the best in a season we've ever seen. We continue onto discussing the Tampa Bay Buccaneers outlook in the NFC South, the Minnesota Vikings and Green Bay Packers in the NFC North and a few trades that would be fun to see before this year's NFL trade deadline. (00:00) - Hello (02:27) - Kansas City Chiefs (12:04) - Drake Maye and the New England Patriots (17:30) - NFC South (22:43) - NFC North (36:08) - Around the NFL Have some interesting takes, some codebreaks or just want to talk to the Green Light Crew? We want to hear from you. Call into the Green Light Hotline and give us your hottest takes, your biggest gripes and general thoughts. Day and night, this hotline is open. Green Light Hotline: ‪(202) 991-0723‬ Also, check out our paddling partners at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Appomattox River Company ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠to get your canoes, kayaks and paddleboards so you're set to hit the river this summer. Green Light's ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠YouTube Channel⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, where you can catch all the latest GL action: Green Light with Chris Long: Subscribe and enjoy weekly content including podcasts, documentaries, live chats, celebrity interviews and more including hot news items, trending discussions from the NFL, MLB, NHL, NBA, NCAA are just a small part of what we will be sharing with you.